Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

The pharmacokinetics and safety of darapladib in subjects with severe renal impairment.

Magee MH, Shaddinger B, Collins D, Siddiqi S, Soffer J.

Br J Clin Pharmacol. 2015 Oct;80(4):654-61. doi: 10.1111/bcp.12661. Epub 2015 Jul 6.

PMID:
25953363
2.

Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population.

Cai A, Li G, Chen J, Li X, Li L, Zhou Y.

BMC Cardiovasc Disord. 2015 Feb 26;15:14. doi: 10.1186/s12872-015-0001-9.

4.

Apolipoprotein CIII regulates lipoprotein-associated phospholipase A2 expression via the MAPK and NFκB pathways.

Han X, Wang T, Zhang J, Liu X, Li Z, Wang G, Song Q, Pang D, Ouyang H, Tang X.

Biol Open. 2015 Apr 2;4(5):661-5. doi: 10.1242/bio.201410900.

5.

Inflammatory therapeutic targets in coronary atherosclerosis-from molecular biology to clinical application.

Linden F, Domschke G, Erbel C, Akhavanpoor M, Katus HA, Gleissner CA.

Front Physiol. 2014 Nov 21;5:455. doi: 10.3389/fphys.2014.00455. eCollection 2014. Review.

6.

Lipoprotein-associated phospholipase A₂ is related to plaque stability and is a potential biomarker for acute coronary syndrome.

Chung H, Kwon HM, Kim JY, Yoon YW, Rhee J, Choi EY, Min PK, Hong BK, Rim SJ, Yoon JH, Lee SJ, Park JK, Kim MH, Jo M, Yang JH, Lee BK.

Yonsei Med J. 2014 Nov;55(6):1507-15. doi: 10.3349/ymj.2014.55.6.1507.

7.

Lp-PLA2 Inhibitors for the Reduction of Cardiovascular Events.

Steen DL, O'Donoghue ML.

Cardiol Ther. 2013 Dec;2(2):125-34. doi: 10.1007/s40119-013-0022-3. Epub 2013 Sep 25.

8.

Clinical usefulness of novel serum and imaging biomarkers in risk stratification of patients with stable angina.

Tsaknis G, Tsangaris I, Ikonomidis I, Tsantes A.

Dis Markers. 2014;2014:831364. doi: 10.1155/2014/831364. Epub 2014 Jun 19. Review.

9.

Unraveling the PAF-AH/Lp-PLA2 controversy.

Stafforini DM, Zimmerman GA.

J Lipid Res. 2014 Sep;55(9):1811-4. doi: 10.1194/jlr.E052886. Epub 2014 Jul 9. No abstract available.

10.

Anti-inflammatory therapies for cardiovascular disease.

Ridker PM, Lüscher TF.

Eur Heart J. 2014 Jul 14;35(27):1782-91. doi: 10.1093/eurheartj/ehu203. Epub 2014 May 26. Review.

11.

Lipoprotein-associated phospholipase A2 and cardiovascular disease risk in HIV infection.

Ross Eckard A, Longenecker CT, Jiang Y, Debanne SM, Labbato D, Storer N, McComsey GA.

HIV Med. 2014 Oct;15(9):537-46. doi: 10.1111/hiv.12143. Epub 2014 Mar 20.

12.

Effect of darapladib treatment on endarterectomy carotid plaque lipoprotein-associated phospholipase A2 activity: a randomized, controlled trial.

Johnson JL, Shi Y, Snipes R, Janmohamed S, Rolfe TE, Davis B, Postle A, Macphee CH.

PLoS One. 2014 Feb 20;9(2):e89034. doi: 10.1371/journal.pone.0089034. eCollection 2014.

13.

Platelet aggregation unchanged by lipoprotein-associated phospholipase A₂ inhibition: results from an in vitro study and two randomized phase I trials.

Shaddinger BC, Xu Y, Roger JH, Macphee CH, Handel M, Baidoo CA, Magee M, Lepore JJ, Sprecher DL.

PLoS One. 2014 Jan 27;9(1):e83094. doi: 10.1371/journal.pone.0083094. eCollection 2014.

14.

n-3 and n-6 Fatty acids are independently associated with lipoprotein-associated phospholipase A2 in the Multi-Ethnic Study of Atherosclerosis.

Steffen BT, Steffen LM, Liang S, Tracy R, Jenny NS, Tsai MY.

Br J Nutr. 2013 Nov 14;110(9):1664-71. doi: 10.1017/S0007114513000949. Epub 2013 Apr 3.

15.

Selective inhibitors and tailored activity probes for lipoprotein-associated phospholipase A(2).

Nagano JM, Hsu KL, Whitby LR, Niphakis MJ, Speers AE, Brown SJ, Spicer T, Fernandez-Vega V, Ferguson J, Hodder P, Srinivasan P, Gonzalez TD, Rosen H, Bahnson BJ, Cravatt BF.

Bioorg Med Chem Lett. 2013 Feb 1;23(3):839-43. doi: 10.1016/j.bmcl.2012.11.061. Epub 2012 Dec 2.

16.

Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study.

Davidson JE, Lockhart A, Amos L, Stirnadel-Farrant HA, Mooser V, Sollberger M, Regeniter A, Monsch AU, Irizarry MC.

Alzheimers Res Ther. 2012 Dec 7;4(6):51. doi: 10.1186/alzrt154. eCollection 2012.

17.

Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.

Rosenson RS, Stafforini DM.

J Lipid Res. 2012 Sep;53(9):1767-82. doi: 10.1194/jlr.R024190. Epub 2012 Jun 4. Review.

18.

Determination of phospholipase activity of PAF acetylhydrolase.

Stafforini DM, McIntyre TM.

Free Radic Biol Med. 2013 Jun;59:100-7. doi: 10.1016/j.freeradbiomed.2012.05.031. Epub 2012 May 29.

19.

Circulating and PBMC Lp-PLA2 associate differently with oxidative stress and subclinical inflammation in nonobese women (menopausal status).

Paik JK, Kim JY, Kim OY, Lee Y, Jeong TS, Sweeney G, Jang Y, Lee JH.

PLoS One. 2012;7(2):e29675. doi: 10.1371/journal.pone.0029675. Epub 2012 Feb 16.

20.

Translational studies of lipoprotein-associated phospholipase A₂ in inflammation and atherosclerosis.

Ferguson JF, Hinkle CC, Mehta NN, Bagheri R, Derohannessian SL, Shah R, Mucksavage MI, Bradfield JP, Hakonarson H, Wang X, Master SR, Rader DJ, Li M, Reilly MP.

J Am Coll Cardiol. 2012 Feb 21;59(8):764-72. doi: 10.1016/j.jacc.2011.11.019.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk